Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: But following a nationwide lockdown to curb the spread of the coronavirus, the 42-year-old vendor has turned to making plastic face shields for frontline medical workers instead. “I was once a patient myself and I feel like my family owes doctors a lot”, said Linh, who received hospital treatment a few years ago for a blood-related illness. “I want to make these shields to keep them healthy. If they are healthy, then they can protect us”. Last week, Vietnam began a 15-day social distancing campaign to slow the spread of the virus that has seen most non-essential businesses shut, including Linh’s stall. There have been 241 reported cases of the coronavirus in Vietnam and no reported deaths, according to the health ministry. Aggressive contact tracing and a mass quarantine programme have helped keep that tally low. When the lockdown began, Linh assembled a group of family members, friends and fellow vendors to start making the face shields. They can be worn in addition to face masks to better protect medical workers from the tiny virus-carrying droplets released by infected patients. In just a few days, Linh and her gang of volunteers made almost 1,000 face shields, she said, and distributed them to at least three nearby hospitals. Linh said she had drawn on her experience as a hat vendor to line the shields with comfortable padding. She watched media reports of doctors in the United States and consulted a friend who works as a nurse there to perfect the design, she said. The finishing touch? A sticker, with an important message to Vietnam’s medical workers: “Fight Covid-19 disease”. “Keep believing, because we are always with you”. (This story is refiled to correct dateline)
[A]: Vietnamese hat seller turns to homemade face shields in virus fight.


[Q]: The story reports not only the cost of the blood test ($60), but the cost to detect one case (including follow-up), which the researchers calculated to be $28,600. This is excellent context. The story would have been better if it had noted that the people included in this study were at unusually high risk for developing this cancer. The 34 cases found after screening 20,000 people is almost 200 times the typical annual rate in the US and other countries (less than 1 per 100,000 people per year). The ultimate measure of cost is cost-effectiveness (cost per life-year saved) which requires survival data. These analyses can also be adjusted for quality of life. While most of this story is careful to note that this test has yet to show clinical effectiveness, that caution is trampled by the claim that this blood test “boosted patients’ chances of survival,” something that this type of study cannot determine. The claim that this test is more accurate than existing methods is also premature, since the study did not directly compare the blood test to existing methods. Finding more early-stage cancers is a necessary but hardly sufficient step in the pathway of demonstrating benefit for a new screening test. Clinical trials are needed to address issues of false positives, over diagnosis, over treatment, and survival. The story reports that developers of this blood test still need to show low rates of false positive or negative results. A low false negative rate means there are fewer missed cases of serious disease. The trade-off, though, is a higher false positive rate. All positive tests will need to be evaluated with a gold standard diagnostic test and the safety, acceptability, and costs of that gold standard test will profoundly affect the uptake of the new screening test. While the story reports that this study was a “proof-of-concept” experiment, it then says the test boosted survival, something that can only be known after directly comparing the new test to existing methods. Making treatment “dramatically more effective” can be proven only with randomized trials. All screening tests that can detect cancers at an earlier stage will be associated with an apparent increase in survival time, but as explained in more detail below, this does not necessarily mean that patients with screen-detected cancers actually live longer than they would have otherwise. Efficacy can be established only with an RCT. The story could have done a better job pointing out the many limitations in the work. For example, there was no follow-up testing for people who had negative blood test results. Even though the researchers surveyed participants a year after the testing, they didn’t produce any data on how many of the people with negative blood tests actually had cancer. What’s more, the researchers compared the survival rates of their patients to a different group of cancer patients from another study, which raises questions about how comparable the groups really are. There was also no discussion of the possibility that at least some of the tumors discovered through this screening might not have developed into dangerous cancers. The story does not address lead-time bias (that longer survival might be at least partly due to finding the tumor earlier in its natural course, rather than to just the effect of treatment). The researchers noted that the effect of lead time bias can only really be known through a randomized, controlled trial. We will rate the story satisfactory on this criterion because it is careful to note that this test is not ready for clinical use and that the study results apply to only one type of cancer. However, the story would have been better if it had pointed out just how rare this cancer is, less than one case per 100,000 people in the US per year. That is about 3,000 cases in the US per year — out of about 1.7 million cancers diagnosed annually. And the comment that the cancer “is prevalent” in southern China and Southeast Asia may be misleading. While it may occur more often in the region, rates are still on the order of 10 to 20 per 100,000 which is hardly widespread. The story squeaks by on this criterion because it includes a quote from an editorial in the journal that was written by an independent source. It would have been more useful to readers to include more comment and context from someone without financial ties to this study. The story is upfront about the financial interests of the researchers themselves and the company that owns the rights to their work, noting the keen interest in bringing this test to market. Although the story reports that “that nasopharyngeal carcinoma typically goes undetected until later on, when patients report symptoms such as recurring nosebleeds,” it does not tell readers anything about how often these cancers are found at an early stage. Readers are not given a sense of how patients typically fare with existing methods of diagnosis. The story clearly reports that the test is still experimental and that developers have yet to show that it could be practical and effective in clinical practice. The story highlights the desire for a new blood test that could be clinically useful. The story doesn’t appear to rely on a news release. It includes quotes from a telephone interview with an executive at the company developing this test.
[A]: Silicon Valley Startup Grail Sees Hope for Cancer Blood Test


[Q]: Subway, Starbucks, KFC and Domino’s Pizza were among the industry leaders graded “F” for their antibiotic policies in the report from consumer and health groups, titled “Chain Reaction,” released on Tuesday. The groups, which did not release results to companies prior to publication, based their grades on public statements, survey responses and correspondence with individual chains. As a result, companies given failing grades were not immediately able to comment. An estimated 70 percent of antibiotics important to human health are sold for use in meat and dairy production. Concern is growing among public health experts that the overuse of such drugs, particularly those important to human medicine, are contributing to rising numbers of life-threatening human infections from antibiotic-resistant bacteria dubbed “superbugs.”  The U.S. Centers for Disease Control and Prevention (CDC) estimates that 2 million people are infected with drug resistant bacteria each year and 23,000 die. “From bacon cheeseburgers to chicken nuggets, most meat served by America’s chain restaurants comes from animals raised in industrial-scale facilities, where they are routinely fed antibiotics to prevent disease that is easily spread in crowded, unsanitary, stressful conditions,” said Kari Hamerschlag, a lead author of the report who is senior program manager at Friends of the Earth. Subway was cited, in particular, for failing to publicly state a policy or plan to cut antibiotic use in the meats it buys, despite repeated requests by the report’s authors for clarification. Chipotle Mexican Grill and Panera Bread, were top finishers with “A” grades. These popular chains have won loyal followings for policies that include strict limits on antibiotic use. Chick-fil-A, which is making meaningful progress toward its goal of only buying chicken raised without antibiotics by 2019, got a “B” in the report. McDonald’s Corp and Dunkin’ Donuts got “C” grades. McDonald’s plans to only source chicken raised without antibiotics important to human medicine by 2017. Dunkin’ Donuts aims to prohibit suppliers from using medically important antibiotics or antimicrobials in healthy animals, but it has not set a timeline.
[A]:
U.S. fast-food meat still mostly raised on antibiotics: consumer groups.